Immunohistochemical localisation of intravitreally injected bevacizumab at the posterior pole of the primate eye: Implication for the treatment of retinal vein occlusion

British Journal of Ophthalmology

Volumn 92, Issue 10, 2008, Pages 1424-1428

  Julien, S ^a   Heiduschka, P ^a   Hofmeister, S ^a   Schraermeyer, U ^a  

^a Institute for Ophthalmic Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG PENETRATION; ENUCLEATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MONKEY; NONHUMAN; OPTIC NERVE; PHOTORECEPTOR; PRIORITY JOURNAL; RETINA FOVEA; RETINA GANGLION CELL; RETINA MACULA EDEMA; RETINA MACULA LUTEA; RETINA NEUROEPITHELIAL LAYER; RETINA VEIN OCCLUSION; TISSUE SECTION; TREATMENT DURATION;

ANIMALS; ANTIBODIES, MONOCLONAL; IMMUNOHISTOCHEMISTRY; MACACA FASCICULARIS; MACULAR EDEMA; OPTIC NERVE; RETINA; RETINAL VEIN OCCLUSION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 53649101192     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2008.141317     Document Type: Article

References (20)

1. Noma H, Funatsu H, Yamasaki M, et al. Pathogenesis of macular oedema with branch retinal vein occlusion and intraocular levels of vascular endotheliel growth factor and interleukin-6. Am J Ophthalmol 2005;140:256-61.
2. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularisatjon and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002;120:1644-50.
3. Adamis AP, Shima DT. Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovasculansation in a nonhuman primate. Arch Ophthalmol 1996;114:66-71.
4. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-5.
5. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab for macular oedema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-9.
6. iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular oedema in central retinal vein occlusion: a short-term study. Retina 2006;26:279-84.
7. Avery RL, Pieramici DJ. Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72.
8. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab (Avastin) treatment of choroidal neovascularisation secondary to age-related macular degeneration. Retina 2006;26:383-90.
9. Rich RM, Rosenfeld PJ, Puliafrto CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
10. Ferrara DC, Koizumi H, Spaide RF. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 2007;144:864-71.
11. Kriechyni K, Michels S, Prager F. et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008;92:2518-22.
12. Krutzer TC, Alge CS, Wolf AH, et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 2008;92:351-5.
13. Hsa J, Kaiser RS, Sivaligam A, et al. Intravitreal bevacizumab (Avastin) in central retinal vein occlusion. Retina 2007;27:1013-19.
14. Central Vein Occlussion Study Group. Evaluation of grid pattern photocoagulation for macula oedema in central vein occlusion. Ophthalmology 1995;102:1425-33.
15. Ips MS, Gottlieb JL, Kahana A, et al. Intravitreal triamcinolone for the treatment of macular oedema associated with central retinal vein occlusion. Arch Ophthalmol 2004;122:1131-6.
16. Williamson TH, O'Donnell A. Intravitreal triamcinolone acetoride for cystoid macular oedema in nonischemic central retinal vein occlusion. Am J Ophthalmol 2005;139:860-6.
17. Heiduschka P, Fietz H, Hofmeister S. et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814-23.
18. Simerre Plantel V, Guerrin M, Chollet P, et al. Vasculotropin-VEGF stimulates retinal capillary endothelial cells through an autocrine pathway. Invest Ophthalmol Vis Sci 1994;35:3393-400.
19. Peturs S, Heiduschcka P, Julien S, et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007;143:995-1002.
20. Slen MA, Ilson D, Kelsen DP. Thrombembolic events in gastric cancer high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 2005;23:2574-6.